(Reuters) – Valeant Pharmaceuticals International Inc is planning to appoint a new CEO as Chief Executive Michael Pearson remains hospitalized, the Wall Street Journal said, citing people familiar with the matter. The new chief executive would replace the committee currently running the company, the newspaper said. Potential new chief executive candidates include Chief Financial Officer Robert Rosiello and Howard Schiller, a Valeant director who resigned as chief financial officer last year, the Journal reported.
Original post:
Valeant plans to appoint new CEO as Pearson remains hospitalized: WSJ
